| Purpose of the guideline: |
In recent years, with the progress in clinical practice and research, neuroimaging biomarkers has greatly promoted the diagnosis, classification and prognosis evaluation of dementia and cognitive impairment. For example,neurodegenerative dementia, especially represented by Alzheimer's disease (AD), could even been definitely diagnosed based on in vivo imaging technology rather than biopsy. However, there remains few available schemes or consensus on when to use of neuroimaging technology and how to interpret the results reasonably. Therefore, the work group, composed of many well-known experts in cognitive impairment and neuroimaging, updated former version of Advice on Diagnostic Process of Neuroimaging in Dementia and Cognitive Impairment (2017, Wang Gang) and first established this experts consensus on neuroimaging diagnosis of dementia and cognitive impairment in China based on clinical experience and latest progress in imaging research. It is expected that with the summary of practical experience and research progress, this guideline will continue to be updated and revised. |
